Triamcinolone Acetonide


Burel Pharmaceuticals, Llc
Human Prescription Drug
NDC 35573-404
Triamcinolone Acetonide is a human prescription drug labeled by 'Burel Pharmaceuticals, Llc'. National Drug Code (NDC) number for Triamcinolone Acetonide is 35573-404. This drug is available in dosage form of Paste. The names of the active, medicinal ingredients in Triamcinolone Acetonide drug includes Triamcinolone Acetonide - 1 mg/g . The currest status of Triamcinolone Acetonide drug is Active.

Drug Information:

Drug NDC: 35573-404
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Triamcinolone Acetonide
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Triamcinolone Acetonide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Burel Pharmaceuticals, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Paste
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:TRIAMCINOLONE ACETONIDE - 1 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:DENTAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 May, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 12 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA205592
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Burel Pharmaceuticals, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1085728
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0335573404543
UPC stands for Universal Product Code.
NUI:N0000175576
N0000175450
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:F446C597KA
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:Corticosteroid Hormone Receptor Agonists [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Corticosteroid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:Corticosteroid Hormone Receptor Agonists [MoA]
Corticosteroid [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
35573-404-541 TUBE in 1 CARTON (35573-404-54) / 5 g in 1 TUBE09 May, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Triamcinolone acetonide triamcinolone acetonide gelatin pectin carboxymethylcellulose sodium high density polyethylene mineral oil triamcinolone acetonide triamcinolone acetonide light beige

Indications and Usage:

Indications and usage triamcinolone acetonide dental paste, usp 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.

General Precautions:

General triamcinolone acetonide dental paste may cause local adverse reactions. if irritation develops, triamcinolone acetonide dental paste should be discontinued and appropriate therapy instituted. allergic contact sensitization with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. such an observation should be corroborated with appropriate diagnostic patch testing. if concomitant mucosal infections are present or develop, an appropriate antifungal or antibacterial agent should be used. if a favorable response does not occur promptly, use of triamcinolone acetonide dental paste should be discontinued until the infection has been adequately controlled. if significant regeneration or repair of oral tissues has not occurred in seven days, additional investigation into the etiology of the oral lesion is advised. systemic absorption of topical corticosteroids has produ
ced reversible hypothalamic-pituitary-adrenal (hpa) axis suppression, manifestations of cushing's syndrome, hyperglycemia, glucosuria, and other adverse effects known to occur with parenterally-administered steroid preparations; therefore, it may be advisable to periodically evaluate patients on prolonged therapy with corticosteroid-containing dental pastes for evidence of hpa axis suppression (see precautions, laboratory tests ). if hpa axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application. recovery of hpa axis function is generally prompt and complete upon discontinuation of therapy.

Dosage and Administration:

Dosage and administration press a small dab (about ¼ inch) to the lesion until a thin film develops. a larger quantity may be required for coverage of some lesions. for optimal results use only enough to coat the lesion with a thin film. do not rub in. attempting to spread this preparation may result in granular, gritty sensation and cause it to crumble. after application, however, a smooth, slippery film develops. the preparation should be applied at bedtime to permit steroid contact with the lesion throughout the night. depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. if significant repair or regeneration has not occurred in seven days, further investigation is advisable.

Contraindications:

Contraindications triamcinolone acetonide dental paste is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.

Adverse Reactions:

Adverse reactions the following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa. also, see precautions for potential effects of systemic absorption. to report suspected adverse reactions, contact cosette pharmaceuticals, inc. at 1-800-922-1038 or fda at 1-800-fda-1088 or www.fda.gov/medwatch .

Use in Pregnancy:

Pregnancy category c teratogenic effects triamcinolone acetonide has been shown to induce teratogenic effects in several species. in mice and rabbits, triamcinolone acetonide induced an increased incidence of cleft palate at dosages of approximately 120 mcg/kg/day and 24 mcg/kg/day, respectively (approximately 12 times and 10 times the amount in a typical daily human dose of triamcinolone acetonide dental paste when compared following normalization of the data on the basis of body surface area estimates, respectively). in monkeys, triamcinolone acetonide induced cranial skeletal malformations at the lowest dosage studied (500 mcg/kg/day),which was approximately 200 times the amount in a typical daily human dose of triamcinolone acetonide dental paste when compared following normalization of the data on the basis of body surface area estimates. there are no adequate and well-controlled studies in pregnant women. however, a retrospective analysis of birth defects among children born to m
others that used drugs of the same class as triamcinolone acetonide dental paste (corticosteroids) during pregnancy found an approximately 3 times increased incidence of cleft palate. triamcinolone acetonide dental paste should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Pediatric use the safety and efficacy of triamcinolone acetonide dental paste in children is unknown. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. administration of corticosteroid-containing dental pastes to children should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.

Geriatric Use:

Geriatric use clinical studies of triamcinolone acetonide dental paste did not include sufficient numbers of subjects age 65 and older to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Description:

Description triamcinolone acetonide dental paste, usp 0.1%, contains the corticosteroid triamcinolone acetonide in an adhesive vehicle suitable for application to oral tissues. triamcinolone acetonide is designated chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. the structural formula of triamcinolone acetonide is as follows: each gram of triamcinolone acetonide dental paste contains 1 mg triamcinolone acetonide in an emollient dental paste containing gelatin, pectin, and carboxymethylcellulose sodium in a plasticized hydrocarbon gel (a polyethylene and mineral oil gel base). structuralformula

Clinical Pharmacology:

Clinical pharmacology like other topical corticosteroids, triamcinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. the mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. however, corticosteroids are thought to act by the induction of phospholipase a 2 inhibitory proteins, collectively called lipocortins. it is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. arachidonic acid is released from membrane phospholipids by phospholipase a 2 . pharmacokinetics the extent of absorption through the oral mucosa is determined by multiple factors including the vehicle, the integrity of the mucosal barrier, the duration of therapy, and the presence of inflammation and/or other disease processes. once absorbed through the mucous membranes, the disposition of corticostero
ids is similar to that of systemically administered corticosteroids. corticosteroids are bound to the plasma proteins in varying degrees. corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys; some corticosteroids and their metabolites are also excreted into the bile.

Pharmacokinetics:

Pharmacokinetics the extent of absorption through the oral mucosa is determined by multiple factors including the vehicle, the integrity of the mucosal barrier, the duration of therapy, and the presence of inflammation and/or other disease processes. once absorbed through the mucous membranes, the disposition of corticosteroids is similar to that of systemically administered corticosteroids. corticosteroids are bound to the plasma proteins in varying degrees. corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys; some corticosteroids and their metabolites are also excreted into the bile.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility animal studies have not been performed to evaluate triamcinolone acetonide for potential to induce carcinogenesis, mutagenesis, or impairment of fertility.

How Supplied:

How supplied triamcinolone acetonide dental paste, usp 0.1% is supplied in tubes containing 5 g of dental paste (ndc 35573-404-54 ). storage keep tightly closed. store at 20°-25°c (68°-77°f) [see usp controlled room temperature]. marketed by: burel pharmaceuticals, llc mason, oh 45040 usa rev. 10/2021 8-0655burlnc2 vc7585

Information for Patients:

Information for the patient patients using topical corticosteroids should receive the following information and instructions: this medication is to be used as directed by the physician or dentist. it is for oral use only; it is not intended for ophthalmic or dermatological use. patients should be advised not to use this medication for any disorder other than for which it was prescribed. patients should report any signs of adverse reactions. as with other corticosteroids, therapy should be discontinued when control is achieved. if no improvement is seen within 2 weeks, contact the physician or dentist.

Package Label Principal Display Panel:

Principal display panel ndc 35573-404-54 triamcinolone acetonide dental paste, usp 5 g rx only for topical use in adjunctive treatment of oral lesions burel pharmaceuticals, llc. carton5g tube5g


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.